KYMR Key Statistics, Chart & Performance
The current stock price of KYMR is 73.46 USD. In the past month the price increased by 10.27%. In the past year, price increased by 92.45%.
KYMR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.7 | 395.77B | ||
| AMGN | AMGEN INC | 15.1 | 177.79B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.98 | 118.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.61B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 796.86 | 53.69B | ||
| INSM | INSMED INC | N/A | 37.34B | ||
| NTRA | NATERA INC | N/A | 34.33B | ||
| BIIB | BIOGEN INC | 10.91 | 26.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.05 | 21.65B | ||
| INCY | INCYTE CORP | 16.61 | 20.94B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About KYMR
Company Profile
Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company is headquartered in Watertown, Massachusetts and currently employs 225 full-time employees. The company went IPO on 2020-08-21. The firm is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The firm's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. The company is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. The company is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.
Company Info
KYMERA THERAPEUTICS INC
500 North Beacon Street, 4Th Floor
Watertown MASSACHUSETTS 02139 US
CEO: Nello Mainolfi
Employees: 225
Phone: 18572855314
KYMERA THERAPEUTICS INC / KYMR FAQ
Can you describe the business of KYMERA THERAPEUTICS INC?
Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company is headquartered in Watertown, Massachusetts and currently employs 225 full-time employees. The company went IPO on 2020-08-21. The firm is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The firm's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. The company is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. The company is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.
What is the stock price of KYMERA THERAPEUTICS INC today?
The current stock price of KYMR is 73.46 USD. The price increased by 1.45% in the last trading session.
What is the dividend status of KYMERA THERAPEUTICS INC?
KYMR does not pay a dividend.
What is the ChartMill rating of KYMERA THERAPEUTICS INC stock?
KYMR has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of KYMERA THERAPEUTICS INC (KYMR) based on its PE ratio?
KYMERA THERAPEUTICS INC (KYMR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.59).
Would investing in KYMERA THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on KYMR.
Can you provide the number of employees for KYMERA THERAPEUTICS INC?
KYMERA THERAPEUTICS INC (KYMR) currently has 225 employees.
KYMR Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to KYMR. When comparing the yearly performance of all stocks, KYMR is one of the better performing stocks in the market, outperforming 94.15% of all stocks.
KYMR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KYMR. While KYMR seems to be doing ok healthwise, there are quite some concerns on its profitability.
KYMR Financial Highlights
Over the last trailing twelve months KYMR reported a non-GAAP Earnings per Share(EPS) of -3.59. The EPS decreased by -58.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.78% | ||
| ROE | -31.19% | ||
| Debt/Equity | 0 |
KYMR Forecast & Estimates
29 analysts have analysed KYMR and the average price target is 111.78 USD. This implies a price increase of 52.17% is expected in the next year compared to the current price of 73.46.
For the next year, analysts expect an EPS growth of -22.28% and a revenue growth 7.16% for KYMR